Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic
challenge with increasingly recognized different phenotypes among variable patient …

Atopic dermatitis (AD) is a common inflammatory skin condition that has traditionally been
considered a paradigmatic type 2 immunity (T2)‐driven disease. Interleukin (IL)‐4 and IL‐13 …

Background Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13,
prevents the formation of the interleukin-4Rα–interleukin-13Rα1 heterodimer receptor …

The evidence‐and consensus‐based guideline on atopic eczema was developed in
accordance with the EuroGuiDerm Guideline and Consensus Statement Development …

The evidence‐and consensus‐based guideline on atopic eczema was developed in
accordance with the EuroGuiDerm Guideline and Consensus Statement Development …

Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis
is made using evaluated clinical criteria. Disease activity and burden are best measured …

Background Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with …

Importance Interleukin 13 (IL-13) is a central pathogenic mediator driving multiple features of
atopic dermatitis (AD) pathophysiology. Objective To evaluate the efficacy and safety of …

Accumulating data on cellular and molecular pathways help to develop novel therapeutic
strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic …

Background IL-13 has an important role in atopic dermatitis (AD) pathogenesis.
Tralokinumab is a fully human mAb that potently and specifically neutralizes IL-13. Objective …